For this reason, the use of anti-VEGF therapy in asthma seems to be a more effective treatment for epithelial barrier reconstruction and remodeling than, e.g., corticosteroid treatment and TNF-α inhibition, which were not effective in increasing E-cadherin and β-catenin levels [140]. The gene discussed is VEGFA; the disease is asthma.